loader image
Monday, May 6, 2024
80.1 F
McAllen
We Welcome your Press Release
- Advertisement -

Baylor Scott & White Health’s 15 Years of Research Brings More Access to Innovative Heart Care

Translate to Spanish or other 102 languages!

System’s research expertise helps introduce new era in heart valve surgery

Mega Doctor News

- Advertisement -

Newswise — On Aug. 16, the U.S. Food and Drug Administration (FDA) approved a minimally invasive open-heart surgery alternative for low surgical-risk patients following the successful outcome of the PARTNER 3 and Evolut LR clinical trials.

Baylor Scott & White The Heart Hospital – Plano and Baylor Scott & White Medical Center – Temple participated in the PARTNER 3 trial and Baylor Scott & White Heart and Vascular Hospital – Dallas participated in the Evolut LR trial, following FDA approval of transcatheter aortic valve replacement (TAVR) for inoperable patients in 2012, high-risk patients in 2014 and medium-risk patients in 2017.

“This is a momentous shift to have a disease that’s historically been mainly treated by open-heart surgery now treated with a catheter-based approach,” said Michael Mack, MD, co-principal Investigator of the PARTNER 3 Trial and medical director of cardiovascular service line for Baylor Scott & White Health. “This approval underscores the importance and value of this research and demonstrates our commitment to improve care options for patients with aortic stenosis.”

- Advertisement -

Baylor Scott & White Health hospitals enrolled the highest number of enrollees in the two trials combined of any health system in the U.S. Baylor Scott & White’s  15-year history with TAVR began in 2004 in Leipzig, Germany, with investigators from Baylor Scott & White The Heart Hospital – Plano (then The Heart Hospital Baylor Plano) working with German colleagues. TAVR was performed on humans in early clinical trials less than three years later in the US. Baylor Scott & White is home to Texas’ largest TAVR program, having performed more than 3,600 TAVRs and is a top-five provider of TAVR nationally.

An estimated 1.5 million people in the U.S. have  aortic stenosis, which is a narrowing of the main heart valve that impedes blood flow from the heart Unlike traditional open-heart surgery, TAVR allows physicians to deliver the new aortic valve via catheter usually through a blood vessel in the leg. This approach has decreased complications and shortened recovery time to one, rather than several, days in the hospital.

Four Baylor Scott & White hospitals offer TAVR:

  • Baylor Scott & White The Heart Hospital – Plano
  • Baylor Scott & White Heart and Vascular Hospital – Dallas
  • Baylor Scott & White All Saints Medical Center – Fort Worth
  • Baylor Scott & White Medical Center – Temple

TAVR research at all facilities is led through Baylor Scott & White Research Institute. Learn more about Baylor Scott & White Health’s TAVR clinical research on Scrubbing.In

- Advertisement -

Learn more about Baylor Scott & White Health’s heart valve disease treatment options

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

World’s First Genetically-Edited Pig Kidney Transplanted into Living Human

Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health care system, announced the world’s first successful transplant of a genetically-edited pig (porcine) kidney into a 62-year-old man living with end-stage kidney disease (ESKD).

ATV Injury Prevention INFO Streaming on Me Gusta TV

Welcome to a special Me Gusta TV broadcast hosted by Mega Doctor News. Today, we bring you an essential event videotaped in Edinburg, Texas, focusing on community safety and health.

A Message from Dr. Zaafran’s, Texas Medical Board President

In an inspiring gesture of gratitude and recognition, Dr. Sherif Zaafran, President of the Texas Medical Board, extends a heartfelt thank you to physicians nationwide ahead of the upcoming National Doctor's Day on March 30th.

Colorectal cancer ‘not an old people’s disease anymore’

In the last 30 years, the incidence of colorectal cancer has gone up by 50% for people under 50.  By 2030, just six years from now, colorectal cancer is predicted to be the leading cause of cancer death for people under 50.
- Advertisement -
×